Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma
Status:
Recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The study is a open-label, single-arm, multicenter, phase Ib/II trial assessing the efficacy
of sacituzumab-govitecan for metastatic esophagogastric adenocarcinoma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest